A major challenge in the immunotherapy of solid tumors lies in the ability to overcome multiple immune escape mechanisms initiated and/or manifest in the tumor microenvironment.Studies from our laboratory have demonstrated that antigen presentation in the context of such tumors can be inhibited and/or skewed towards an ineffective response due to these pathways.Studies to be presented describe our development and clinical translation of approaches using engineered poxvirus administered into the tumor microenvironment with the goal of overcoming immune escape and leading to the development of effective antitumor immunity.